APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Somatostatin Analogues (LA SSAs)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Long-acting Somatostatin Analogues (LA SSAs) Market Analysis and Forecast 2026-2032

29 December 2025196 pages

Choose your research edition.

Industry ResearchLong-acting Somatostatin Analogues (LA SSAs) Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Somatostatin Analogues (LA SSAs) Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Long-acting Somatostatin Analogues (LA SSAs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Somatostatin Analogues (LA SSAs) Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Somatostatin Analogues (LA SSAs) Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Long-acting Somatostatin Analogues (LA SSAs) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Long-acting Somatostatin Analogues (LA SSAs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Long-acting Somatostatin Analogues (LA SSAs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Long-acting Somatostatin Analogues (LA SSAs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Long-acting Somatostatin Analogues (LA SSAs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Long-acting Somatostatin Analogues (LA SSAs) include Chiesi Farmaceutici S.p.A, Ipsen, Recordati Rare Diseases, Novartis and Teva, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Long-acting Somatostatin Analogues (LA SSAs), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Long-acting Somatostatin Analogues (LA SSAs), also provides the sales of main regions and countries. Of the upcoming market potential for Long-acting Somatostatin Analogues (LA SSAs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Long-acting Somatostatin Analogues (LA SSAs) sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Long-acting Somatostatin Analogues (LA SSAs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Long-acting Somatostatin Analogues (LA SSAs) sales, projected growth trends, production technology, application and end-user industry.

Long-acting Somatostatin Analogues (LA SSAs) Segment by Company

Chiesi Farmaceutici S.p.A

Ipsen

Recordati Rare Diseases

Novartis

Teva

Long-acting Somatostatin Analogues (LA SSAs) Segment by Type

Injections

Oral Capsules

Long-acting Somatostatin Analogues (LA SSAs) Segment by Application

Neuroendocrine Tumors

Acromegaly

Other

Long-acting Somatostatin Analogues (LA SSAs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Somatostatin Analogues (LA SSAs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Somatostatin Analogues (LA SSAs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Somatostatin Analogues (LA SSAs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Long-acting Somatostatin Analogues (LA SSAs) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Long-acting Somatostatin Analogues (LA SSAs) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-acting Somatostatin Analogues (LA SSAs) sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Injections Major Manufacturers Table 3. Oral Capsules Major Manufacturers Table 4. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Neuroendocrine Tumors Major Manufacturers Table 6. Acromegaly Major Manufacturers Table 7. Other Major Manufacturers Table 8. Long-acting Somatostatin Analogues (LA SSAs) Industry Trends Table 9. Long-acting Somatostatin Analogues (LA SSAs) Industry Drivers Table 10. Long-acting Somatostatin Analogues (LA SSAs) Industry Opportunities and Challenges Table 11. Long-acting Somatostatin Analogues (LA SSAs) Industry Restraints Table 12. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Region (2021-2026) Table 16. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Region (2027-2032) Table 17. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2021-2026) & (K Units) Table 19. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2027-2032) & (K Units) Table 20. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Region (2021-2026) Table 21. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Region (2027-2032) Table 22. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Manufacturers (2021-2026) Table 26. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Long-acting Somatostatin Analogues (LA SSAs) Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Long-acting Somatostatin Analogues (LA SSAs) Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers, Product Type & Application Table 30. Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Long-acting Somatostatin Analogues (LA SSAs) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type (2021-2026) Table 37. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type (2027-2032) Table 38. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 40. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2027-2032) & (K Units) Table 41. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type (2021-2026) Table 42. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type (2027-2032) Table 43. Global Long-acting Somatostatin Analogues (LA SSAs) Price by Type (2021-2026) & (US$/Unit) Table 44. Global Long-acting Somatostatin Analogues (LA SSAs) Price by Type (2027-2032) & (US$/Unit) Table 45. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2021-2026) Table 49. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2027-2032) Table 50. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 52. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2027-2032) & (K Units) Table 53. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application (2021-2026) Table 54. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application (2027-2032) Table 55. Global Long-acting Somatostatin Analogues (LA SSAs) Price by Application (2021-2026) & (US$/Unit) Table 56. Global Long-acting Somatostatin Analogues (LA SSAs) Price by Application (2027-2032) & (US$/Unit) Table 57. Chiesi Farmaceutici S.p.A Company Information Table 58. Chiesi Farmaceutici S.p.A Business Overview Table 59. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 61. Chiesi Farmaceutici S.p.A Recent Development Table 62. Ipsen Company Information Table 63. Ipsen Business Overview Table 64. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 66. Ipsen Recent Development Table 67. Recordati Rare Diseases Company Information Table 68. Recordati Rare Diseases Business Overview Table 69. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 71. Recordati Rare Diseases Recent Development Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Novartis Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 76. Novartis Recent Development Table 77. Teva Company Information Table 78. Teva Business Overview Table 79. Teva Long-acting Somatostatin Analogues (LA SSAs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Teva Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio Table 81. Teva Recent Development Table 82. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2026) & (US$ Million) Table 83. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2027-2032) & (US$ Million) Table 84. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 85. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2027-2032) & (K Units) Table 86. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Type (2021-2026) & (US$/Unit) Table 87. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Type (2027-2032) & (US$/Unit) Table 88. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2026) & (US$ Million) Table 89. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2027-2032) & (US$ Million) Table 90. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 91. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2027-2032) & (K Units) Table 92. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Application (2021-2026) & (US$/Unit) Table 93. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Application (2027-2032) & (US$/Unit) Table 94. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 96. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 97. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 98. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 99. North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 100. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Country (2021-2026) & (US$/Unit) Table 101. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Country (2027-2032) & (US$/Unit) Table 102. United States Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 103. Canada Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 104. Mexico Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 105. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2026) & (US$ Million) Table 106. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2027-2032) & (US$ Million) Table 107. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 108. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2027-2032) & (K Units) Table 109. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Type (2021-2026) & (US$/Unit) Table 110. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Type (2027-2032) & (US$/Unit) Table 111. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2026) & (US$ Million) Table 112. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2027-2032) & (US$ Million) Table 113. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 114. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2027-2032) & (K Units) Table 115. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Application (2021-2026) & (US$/Unit) Table 116. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Application (2027-2032) & (US$/Unit) Table 117. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 119. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 120. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 121. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 122. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 123. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Country (2021-2026) & (US$/Unit) Table 124. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Country (2027-2032) & (US$/Unit) Table 125. Germany Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 126. France Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 127. U.K. Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 128. Italy Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 129. Russia Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 130. Spain Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 131. Netherlands Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 132. Switzerland Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 133. Sweden Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 134. Poland Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 135. China Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2026) & (US$ Million) Table 136. China Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2027-2032) & (US$ Million) Table 137. China Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 138. China Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2027-2032) & (K Units) Table 139. China Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Type (2021-2026) & (US$/Unit) Table 140. China Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Type (2027-2032) & (US$/Unit) Table 141. China Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2026) & (US$ Million) Table 142. China Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2027-2032) & (US$ Million) Table 143. China Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 144. China Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2027-2032) & (K Units) Table 145. China Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Application (2021-2026) & (US$/Unit) Table 146. China Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Application (2027-2032) & (US$/Unit) Table 147. Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2026) & (US$ Million) Table 148. Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2027-2032) & (US$ Million) Table 149. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 150. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2027-2032) & (K Units) Table 151. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Type (2021-2026) & (US$/Unit) Table 152. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Type (2027-2032) & (US$/Unit) Table 153. Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2026) & (US$ Million) Table 154. Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2027-2032) & (US$ Million) Table 155. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 156. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2027-2032) & (K Units) Table 157. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Application (2021-2026) & (US$/Unit) Table 158. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Application (2027-2032) & (US$/Unit) Table 159. Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 161. Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 162. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 163. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 164. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 165. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Country (2021-2026) & (US$/Unit) Table 166. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Country (2027-2032) & (US$/Unit) Table 167. Japan Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 168. South Korea Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 169. India Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 170. Australia Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 171. Taiwan Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 172. Southeast Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 173. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2026) & (US$ Million) Table 174. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2027-2032) & (US$ Million) Table 175. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2026) & (K Units) Table 176. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2027-2032) & (K Units) Table 177. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Type (2021-2026) & (US$/Unit) Table 178. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Type (2027-2032) & (US$/Unit) Table 179. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2026) & (US$ Million) Table 180. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2027-2032) & (US$ Million) Table 181. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2026) & (K Units) Table 182. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2027-2032) & (K Units) Table 183. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Application (2021-2026) & (US$/Unit) Table 184. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Application (2027-2032) & (US$/Unit) Table 185. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 186. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 187. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 188. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 189. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021-2026) & (K Units) Table 190. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2027-2032) & (K Units) Table 191. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Country (2021-2026) & (US$/Unit) Table 192. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Country (2027-2032) & (US$/Unit) Table 193. Brazil Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 194. Argentina Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 195. Chile Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 196. Colombia Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 197. Peru Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 198. Saudi Arabia Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 199. Israel Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 200. UAE Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 201. Turkey Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 202. Iran Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 203. Egypt Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Table 204. Key Raw Materials Table 205. Raw Materials Key Suppliers Table 206. Long-acting Somatostatin Analogues (LA SSAs) Distributors List Table 207. Long-acting Somatostatin Analogues (LA SSAs) Customers List Table 208. Research Programs/Design for This Report Table 209. Authors List of This Report Table 210. Secondary Sources Table 211. Primary Sources List of Figures Figure 1. Long-acting Somatostatin Analogues (LA SSAs) Image Figure 2. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Injections Image Figure 5. Oral Capsules Image Figure 6. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Long-acting Somatostatin Analogues (LA SSAs) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Neuroendocrine Tumors Image Figure 9. Acromegaly Image Figure 10. Other Image Figure 11. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue (2021-2032) & (US$ Million) Figure 13. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Region (2021-2032) Figure 16. Global Long-acting Somatostatin Analogues (LA SSAs) Sales (2021-2032) & (K Units) Figure 17. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Long-acting Somatostatin Analogues (LA SSAs) Sales YoY (2021-2032) & (K Units) Figure 20. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales YoY (2021-2032) & (K Units) Figure 21. China Long-acting Somatostatin Analogues (LA SSAs) Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Long-acting Somatostatin Analogues (LA SSAs) Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Long-acting Somatostatin Analogues (LA SSAs) Sales YoY (2021-2032) & (K Units) Figure 24. Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type (2021-2032) Figure 30. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type (2021-2032) Figure 33. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2021-2032) Figure 36. Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application (2021-2032) Figure 39. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Type (2021-2032) Figure 40. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Type (2021-2032) Figure 41. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Application (2021-2032) Figure 42. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Application (2021-2032) Figure 43. North America Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Country (2021-2032) Figure 44. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Country (2021-2032) Figure 45. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Type (2021-2032) Figure 46. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Type (2021-2032) Figure 47. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Application (2021-2032) Figure 48. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Application (2021-2032) Figure 49. Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Country (2021-2032) Figure 50. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Country (2021-2032) Figure 51. China Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Type (2021-2032) Figure 52. China Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Type (2021-2032) Figure 53. China Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Application (2021-2032) Figure 54. China Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Application (2021-2032) Figure 55. Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Type (2021-2032) Figure 56. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Type (2021-2032) Figure 57. Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Application (2021-2032) Figure 58. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Application (2021-2032) Figure 59. Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Country (2021-2032) Figure 60. Asia Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Country (2021-2032) Figure 61. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Type (2021-2032) Figure 62. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Type (2021-2032) Figure 63. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Application (2021-2032) Figure 64. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Application (2021-2032) Figure 65. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue Share by Country (2021-2032) Figure 66. SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales Share by Country (2021-2032) Figure 67. Long-acting Somatostatin Analogues (LA SSAs) Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Long-acting Somatostatin Analogues (LA SSAs) Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Injections
  • Oral Capsules
Applications
  • Neuroendocrine Tumors
  • Acromegaly
  • Other
Companies covered
  • Chiesi Farmaceutici S.p.A
  • Ipsen
  • Recordati Rare Diseases
  • Novartis
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Long-acting Somatostatin Analogues (LA SSAs) Market by Type
  3. 1.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Injections
  5. 1.2.3 Oral Capsules
  6. 1.3 Long-acting Somatostatin Analogues (LA SSAs) Market by Application
  7. 1.3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Neuroendocrine Tumors
  9. 1.3.3 Acromegaly
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Long-acting Somatostatin Analogues (LA SSAs) Market Dynamics
  1. 2.1 Long-acting Somatostatin Analogues (LA SSAs) Industry Trends
  2. 2.2 Long-acting Somatostatin Analogues (LA SSAs) Industry Drivers
  3. 2.3 Long-acting Somatostatin Analogues (LA SSAs) Industry Opportunities and Challenges
  4. 2.4 Long-acting Somatostatin Analogues (LA SSAs) Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region
  3. 3.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region (2021-2026)
  5. 3.2.3 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Region (2027-2032)
  6. 3.2.4 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region
  9. 3.4.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2021-2026)
  11. 3.4.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Region (2027-2032)
  12. 3.4.4 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Manufacturers
  2. 4.1.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Manufacturers
  6. 4.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Long-acting Somatostatin Analogues (LA SSAs) Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Long-acting Somatostatin Analogues (LA SSAs) Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers, Product Type & Application
  13. 4.7 Global Long-acting Somatostatin Analogues (LA SSAs) Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market CR5 and HHI
  16. 4.8.2 2025 Long-acting Somatostatin Analogues (LA SSAs) Tier 1, Tier 2, and Tier 3
5 Long-acting Somatostatin Analogues (LA SSAs) Market by Type
  1. 5.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type
  2. 5.1.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type
  6. 5.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Type (2021-2032)
  9. 5.3 Global Long-acting Somatostatin Analogues (LA SSAs) Price by Type
6 Long-acting Somatostatin Analogues (LA SSAs) Market by Application
  1. 6.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application
  2. 6.1.1 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application
  6. 6.2.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Market Share by Application (2021-2032)
  9. 6.3 Global Long-acting Somatostatin Analogues (LA SSAs) Price by Application
7 Company Profiles
  1. 7.1 Chiesi Farmaceutici S.p.A
  2. 7.1.1 Chiesi Farmaceutici S.p.A Company Information
  3. 7.1.2 Chiesi Farmaceutici S.p.A Business Overview
  4. 7.1.3 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  6. 7.1.5 Chiesi Farmaceutici S.p.A Recent Developments
  7. 7.2 Ipsen
  8. 7.2.1 Ipsen Company Information
  9. 7.2.2 Ipsen Business Overview
  10. 7.2.3 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  12. 7.2.5 Ipsen Recent Developments
  13. 7.3 Recordati Rare Diseases
  14. 7.3.1 Recordati Rare Diseases Company Information
  15. 7.3.2 Recordati Rare Diseases Business Overview
  16. 7.3.3 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  18. 7.3.5 Recordati Rare Diseases Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Teva
  26. 7.5.1 Teva Company Information
  27. 7.5.2 Teva Business Overview
  28. 7.5.3 Teva Long-acting Somatostatin Analogues (LA SSAs) Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Teva Long-acting Somatostatin Analogues (LA SSAs) Product Portfolio
  30. 7.5.5 Teva Recent Developments
8 North America
  1. 8.1 North America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Type
  2. 8.1.1 North America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2032)
  3. 8.1.2 North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2032)
  4. 8.1.3 North America Long-acting Somatostatin Analogues (LA SSAs) Price by Type (2021-2032)
  5. 8.2 North America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Application
  6. 8.2.1 North America Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2032)
  7. 8.2.2 North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2032)
  8. 8.2.3 North America Long-acting Somatostatin Analogues (LA SSAs) Price by Application (2021-2032)
  9. 8.3 North America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
  10. 8.3.1 North America Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Long-acting Somatostatin Analogues (LA SSAs) Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size by Type
  2. 9.1.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2032)
  3. 9.1.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2032)
  4. 9.1.3 Europe Long-acting Somatostatin Analogues (LA SSAs) Price by Type (2021-2032)
  5. 9.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size by Application
  6. 9.2.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2032)
  7. 9.2.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2032)
  8. 9.2.3 Europe Long-acting Somatostatin Analogues (LA SSAs) Price by Application (2021-2032)
  9. 9.3 Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
  10. 9.3.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Long-acting Somatostatin Analogues (LA SSAs) Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Long-acting Somatostatin Analogues (LA SSAs) Market Size by Type
  2. 10.1.1 China Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2032)
  3. 10.1.2 China Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2032)
  4. 10.1.3 China Long-acting Somatostatin Analogues (LA SSAs) Price by Type (2021-2032)
  5. 10.2 China Long-acting Somatostatin Analogues (LA SSAs) Market Size by Application
  6. 10.2.1 China Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2032)
  7. 10.2.2 China Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2032)
  8. 10.2.3 China Long-acting Somatostatin Analogues (LA SSAs) Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Long-acting Somatostatin Analogues (LA SSAs) Market Size by Type
  2. 11.1.1 Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2032)
  3. 11.1.2 Asia Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2032)
  4. 11.1.3 Asia Long-acting Somatostatin Analogues (LA SSAs) Price by Type (2021-2032)
  5. 11.2 Asia Long-acting Somatostatin Analogues (LA SSAs) Market Size by Application
  6. 11.2.1 Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2032)
  7. 11.2.2 Asia Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2032)
  8. 11.2.3 Asia Long-acting Somatostatin Analogues (LA SSAs) Price by Application (2021-2032)
  9. 11.3 Asia Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
  10. 11.3.1 Asia Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Long-acting Somatostatin Analogues (LA SSAs) Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Long-acting Somatostatin Analogues (LA SSAs) Market Size by Type
  2. 12.1.1 SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Long-acting Somatostatin Analogues (LA SSAs) Price by Type (2021-2032)
  5. 12.2 SAMEA Long-acting Somatostatin Analogues (LA SSAs) Market Size by Application
  6. 12.2.1 SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Long-acting Somatostatin Analogues (LA SSAs) Price by Application (2021-2032)
  9. 12.3 SAMEA Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
  10. 12.3.1 SAMEA Long-acting Somatostatin Analogues (LA SSAs) Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Long-acting Somatostatin Analogues (LA SSAs) Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Long-acting Somatostatin Analogues (LA SSAs) Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Long-acting Somatostatin Analogues (LA SSAs) Value Chain Analysis
  2. 13.1.1 Long-acting Somatostatin Analogues (LA SSAs) Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Long-acting Somatostatin Analogues (LA SSAs) Production Mode & Process
  6. 13.2 Long-acting Somatostatin Analogues (LA SSAs) Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Long-acting Somatostatin Analogues (LA SSAs) Distributors
  9. 13.2.3 Long-acting Somatostatin Analogues (LA SSAs) Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst